肺移植受者抗反流手术短期并发症与匹配非移植队列相当
该研究比较肺移植受者与非移植对照接受腹腔镜抗反流手术后的30天再入院率和短期并发症。共纳入1328例患者(55例肺移植,1273例非移植),肺移植组30天再入院率高于全部非移植对照(14.5% vs. 2.8%, p < 0.001),但与1:2倾向性评分匹配的非移植对照相比,30天并发症发生率相当(21.8% vs 14.5%, p = 0.24)。结论提示在移植和食管胃手术经验丰富的大容量中心,肺移植后行腹腔镜抗反流手术是安全的。
要点
- 肺移植受者抗反流术后30天再入院率高于全部非移植对照。
- 与匹配非移植对照相比,肺移植受者30天并发症发生率无显著差异。
- 在大容量移植与食管胃手术中心,肺移植后抗反流手术是安全的。
核心结论
- 在移植和食管胃手术经验丰富的大容量中心,肺移植受者与匹配非移植对照接受腹腔镜抗反流手术后的30天并发症发生率相似。
- 肺移植后行腹腔镜抗反流手术是安全的。
研究设计与样本
- 共纳入1328例患者,其中肺移植受者55例,非移植对照1273例;另采用1:2倾向性评分匹配的非移植对照进行比较。
主要发现
- 肺移植受者术后30天再入院率高于全部非移植对照(14.5% vs. 2.8%, p < 0.001)。
- 与匹配非移植对照相比,肺移植受者食管旁疝患病率更低、疝中位尺寸更小、蠕动强度更高。
- 与匹配非移植对照相比,肺移植受者中位手术时间更短,但中位住院时间更长。
- 肺移植受者与匹配非移植对照术后30天内事件发生率相当(21.8% vs 14.5%, p = 0.24)。
临床怎么用
- 对于肺移植后存在抗反流手术指征的患者,在具备移植和食管胃手术专长的大容量中心可考虑行腹腔镜抗反流手术。
- 术前应评估肺移植受者的合并症负担,并关注术后30天再入院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Safety data on perioperative outcomes of laparoscopic antireflux surgery (LARS) after lung transplantation (LT) are lacking. We compared the 30-day readmission rate and short-term morbidity after LARS between LT recipients and matched nontransplant (NT) controls. METHODS: Adult patients who underwent LARS between January 1, 2015, and October 31, 2021, were included. The participants were divided into two groups: LT recipients and NT controls. First, we compared 30-day readmission rates after LARS between the LT and NT cohorts. Next, we compared 30-day morbidity after LARS between the LT cohort and a 1-to-2 propensity score-matched NT cohort. RESULTS: A total of 1328 patients (55 LT recipients and 1273 NT controls) were included. The post-LARS 30-day readmission rate was higher in LT recipients than in the overall NT controls (14.5% vs. 2.8%, p < 0.001). Compared to matched NT controls, LT recipients had a lower prevalence of paraesophageal hernia, a smaller median hernia size, and higher peristaltic vigor. Also compared to the matched NT controls, the LT recipients had a lower median operative time but a longer median length of hospital stay. The proportion of patients with a post-LARS event within 30 postoperative days was comparable between the LT and matched NT cohorts (21.8% vs 14.5%, p = 0.24). CONCLUSIONS: Despite a higher perceived risk of comorbidity burden, LT recipients and matched NT controls had similar rates of post-LARS 30-day morbidity at our large-volume center with expertise in transplant and foregut surgery. LARS after LT is safe.
引用
- Razia D, Mittal SK, Walia R, et al. Morbidity of antireflux surgery in lung transplant and matched nontransplant cohorts is comparable. Surg Endosc. 2022. PMID: 36131161. doi:10.1007/s00464-022-09598-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。